Excel Diagnostics & Nuclear Oncology Center

The trials here

What the 5 trials at this site are about, from their registry records.

Conditions

• Prostate cancer3 trials
• Pancreatic cancer2 trials
• Glioblastoma1 trial
• Neuroendocrine tumours1 trial

Phase

• Phase 33 trials
• Phase 11 trial
• Phase 21 trial

Status

• Active, not recruiting2 trials
• Recruiting2 trials
• Completed1 trial

Lead sponsor

• Ebrahim S Delpassand1 trial
• Endocyte1 trial
• ITM Solucin GmbH1 trial
• POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company1 trial
• Radiomedix, Inc.1 trial

Running trials

• Recruiting

  Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07733674· Phase 1· Radiomedix, Inc.· Source

  Contact: Susan Cork

• Recruiting

  Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

  NCT06972628· Phase 2· Ebrahim S Delpassand· Source

  Contact: Susan Cork Therapy Coordinator

• Active, not recruiting

  Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment

  NCT04647526· Phase 3· POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company· Source

• Active, not recruiting

  Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

  NCT03049189· Phase 3· ITM Solucin GmbH· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Glioblastoma1 recruiting
• Pancreatic cancer1 recruiting
• Prostate cancer1 recruiting

Closed trials

• Completed

  Study of 177Lu-PSMA-617 In Metastatic Castrate-Resistant Prostate Cancer

  NCT03511664· Phase 3· Endocyte· Source